PX'Therapeutics to open a new cGMP biomanufacturing facility

November 25, 2009

Grenoble, France, November 25th 2009 - PX'Therapeutics SA (formerly known as Protein'eXpert) announces the set up of an additional biomanufacturing unit dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells. This facility, located in the company's Grenoble site, is mainly financed by loans from PX'Therapeutics' bank partners : BNP Paribas and Crédit Coopératif, with the support of OSEO Rhône-Alpes. The cGMP plant will be operational from April 2010 and will allow cell banking as well as preclinical and clinical manufacturing of biotherapeutics (scale: 100-200L). In parallel, PX'Therapeutics plans to upgrade the existing cGMP unit devoted to bacterial and yeast systems with a 100L bioreactor. The extension of the company's production capabilities is part of its development strategy and will mark its tenth anniversary. Indeed, PX'Therapeutics is anticipating strong growth in the next two years, mainly due to the strengthening of its commercial activities in Europe and North America, the set up of new partnerships with big pharmas and the creation of value out of collaborative R&D programs focused on biotherapeutics/vaccine development.  

 

About PX'Therapeutics

PX'Therapeutics, located in Grenoble and Lyon (France) and with a sales office in Cambridge (MA, USA), offers early stage research and cGMP manufacturing contracts focusing on the development of protein therapeutics, monoclonal antibodies and recombinant vaccines. PX'Therapeutics proposes custom programs targeting the generation of murine antibodies, humanization of therapeutic antibodies, protein engineering and optimization, feasibility studies, process development or small scale clinical manufacturing.

PX'Therapeutics has been playing a key role in the discovery, development and production of target or therapeutic proteins, with over 500 projects performed so far. The company has then accumulated a specific and acknowledged expertise in the field of difficult-to-express proteins and developed trusted relationships with more than 140 biotech/pharmaceutical partners and clients in Europe, North America and Japan.

As an example, in 2009, two therapeutic candidates developed by PX'Therapeutics have produced positive results as part of Phase I clinical trials performed in Europe and in the United States.

 

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.